Welcome to our dedicated page for Immatics N.V. Ordinary Shares news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V. Ordinary Shares stock.
Immatics N.V. (NASDAQ: IMTX) is a pioneering clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative T-cell redirecting immunotherapies for cancer treatment. Headquartered in both Germany and Switzerland, Immatics harnesses cutting-edge biotechnology to create transformative therapies aimed at combating various forms of cancer.
The company's core product candidates include adoptive cell therapies and bispecific TCR molecules. These therapies are designed to target tumor-specific antigens identified through Immatics' proprietary and world-leading XPRESIDENT® technology platform. This platform enables the precise identification and validation of tumor targets, ensuring the development of highly specific and effective cancer treatments.
Immatics is structured around two proprietary technology platforms and actively manages eight proprietary development programs, with two programs already in clinical trials as of 2017. The company's robust research pipeline covers more than 100 targets across 20 major solid and liquid tumors, with approximately 80% of these targets being novel discoveries.
Recent financial successes underscore Immatics' growth and potential; the company has raised over $230 million in cash through five financing rounds. This substantial funding supports their mission to advance T-cell redirecting immunotherapies and bring new hope to cancer patients worldwide.
Immatics collaborates with numerous third-party pharmaceutical and biotechnology companies, forming strategic partnerships to further enhance the development and commercialization of their innovative therapies. The company's commitment to innovation and collaboration positions it as a leader in the biopharmaceutical industry.
For more detailed information, including the latest updates and financial results, visit the Immatics website or follow them on Twitter and Xing.
Immatics (NASDAQ: IMTX) reported its Q1 2024 financial results and provided a business update, including clinical data from their ongoing Phase 1 trial of ACTengine® IMA203 targeting PRAME. The trial showed a 55% confirmed objective response rate in heavily pre-treated metastatic melanoma patients, with tumor shrinkage in 87% and a median response duration of 13.5 months. IMA203 maintained a favorable safety profile. A Phase 2/3 trial is planned for 2024.
The company also completed a $201.5 million public offering in January 2024, ending the quarter with $609.7 million in cash and equivalents, funding operations into 2027. Q1 2024 revenues were $32.8 million, largely due to a terminated collaboration, while net loss narrowed to $3.4 million from $21.3 million in Q1 2023. Upcoming milestones include updates on IMA203, IMA203CD8, and TCER® programs in 2H 2024.
FAQ
What is the current stock price of Immatics N.V. Ordinary Shares (IMTX)?
What is the market cap of Immatics N.V. Ordinary Shares (IMTX)?
What does Immatics N.V. do?
What are Immatics' core product candidates?
What is XPRESIDENT® technology?
How many targets does Immatics' research cover?
What is the company's financial status?
Are Immatics' therapies in clinical trials?
Who are Immatics' partners?
Where is Immatics headquartered?
What is the company's mission?
How can I learn more about Immatics?
